Follow-The-Filings

Featured 13F manager

Paulson & Co. Inc. John Paulson

Jersey City, NJ 20 processed 13Fs on this site · 2021 Q3–2026 Q2

  • $2.6B
  • 8 Positions
  • 2026 Q2
  • −17.2% QoQ
  • Top 5 92.3%

John Paulson files Paulson & Co. Inc. as a Form 13F. The latest book is 2026 Q2 at $2.6B, down 17.2% QoQ, led by Madrigal Pharmaceuticals, Perpetua Resources, and Acadian Asset Management.

Portfolio

2026 Q2 · filed 8/14/2026 · 8 long

top 5 92.3% · top 10 100.0%

AUM over time

2026 Q2 $2.6B −17.2% QoQ
2021 Q3 · $3.5B 2021 Q3 · $3.5B
Q3 2021
2021 Q4 · $3.2B · −7.6% QoQ 2021 Q4 · $3.2B · −7.6% QoQ
Q4
2022 Q1 · $3.2B · +0.2% QoQ 2022 Q1 · $3.2B · +0.2% QoQ
Q1 2022
2022 Q2 · $2B · −37.6% QoQ 2022 Q2 · $2B · −37.6% QoQ
Q2
2022 Q3 · $1.4B · −32.6% QoQ 2022 Q3 · $1.4B · −32.6% QoQ
Q3
2022 Q4 · $1.1B · −18.7% QoQ 2022 Q4 · $1.1B · −18.7% QoQ
Q4
2023 Q1 · $1.2B · +8.3% QoQ 2023 Q1 · $1.2B · +8.3% QoQ
Q1 2023
2023 Q2 · $1B · −14.9% QoQ 2023 Q2 · $1B · −14.9% QoQ
Q2
2023 Q3 · $1.1B · +9.2% QoQ 2023 Q3 · $1.1B · +9.2% QoQ
Q3
2023 Q4 · $1.1B · −0.9% QoQ 2023 Q4 · $1.1B · −0.9% QoQ
Q4
2024 Q1 · $1.4B · +30.7% QoQ 2024 Q1 · $1.4B · +30.7% QoQ
Q1 2024
2024 Q2 · $1.4B · −6.6% QoQ 2024 Q2 · $1.4B · −6.6% QoQ
Q2
2024 Q3 · $1.4B · +5.3% QoQ 2024 Q3 · $1.4B · +5.3% QoQ
Q3
2024 Q4 · $1.7B · +15.9% QoQ 2024 Q4 · $1.7B · +15.9% QoQ
Q4
2025 Q1 · $1.7B · +5.8% QoQ 2025 Q1 · $1.7B · +5.8% QoQ
Q1 2025
2025 Q2 · $2B · +15.1% QoQ 2025 Q2 · $2B · +15.1% QoQ
Q2
2025 Q3 · $3B · +47.6% QoQ 2025 Q3 · $3B · +47.6% QoQ
Q3
2025 Q4 · $3.3B · +9.9% QoQ 2025 Q4 · $3.3B · +9.9% QoQ
Q4
2026 Q1 · $3.1B · −4.6% QoQ 2026 Q1 · $3.1B · −4.6% QoQ
Q1 2026
2026 Q2 · $2.6B · −17.2% QoQ 2026 Q2 · $2.6B · −17.2% QoQ
Q2

Book

2023 Q3 2023 Q2 · filed 14 Nov · long equity

Horizon Therapeutics Pub L 21.77% Add +320.6% 2,103,046 $115.69 $243M +1,603,046 +$192M
BHC - Bausch Health Cos 19.45% Hold 26,439,035 $8.22 $217M
AAMI - Brightsphere Invt Group 15.53% Hold 8,950,121 $19.39 $174M
NG - Novagold Res 7.64% Hold 22,226,300 $3.84 $85M
PPTA - Perpetua Resources 7.23% Hold 24,771,542 $3.26 $81M
MDGL - Madrigal Pharmaceuticals 6.53% Add +42.8% 500,000 $146.04 $73M +149,800 −$8M
AU - Anglogold Ashanti 5.42% New 3,833,492 $15.80 $61M +3,833,492 +$61M
THRY - Thryv 3.36% Hold 2,000,000 $18.77 $38M
AEM - Agnico Eagle Mines 3.19% Hold 783,561 $45.45 $36M
Ssr Mining In 2.38% Hold 2,000,000 $13.29 $27M
SA - Seabridge Gold 1.95% Hold 2,070,000 $10.55 $22M
THM — 1.95% Hold 61,930,724 $0.3520 $22M
EQX - Equinox Gold 0.95% Hold 2,500,000 $4.23 $11M
Newmark Group · CL A 0.74% Hold 1,284,625 $6.43 $8M
Trilogy Metals 0.63% Hold 14,326,996 $0.4900 $7M
Tellurian 0.55% Hold 5,340,663 $1.16 $6M
BABA - Alibaba Group 0.39% Hold 50,000 $86.74 $4M
Iamgold 0.36% Hold 1,850,000 $2.15 $4M

Exits / last held

not current holdings · last reported size, unchanged · gone vs 2023 Q2

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
AU - Anglogold Ashanti 7.89% Exit 0 $21.09 $81M −3,833,492 −$81M
NEM - Newmont 1.88% Exit 0 $42.66 $19M −452,000 −$19M
Iveric Bio 0.10% Exit 0 $39.36 $984K −25,000 −$984K
Diversey 0.04% Exit 0 $8.40 $420K −50,000 −$420K

* Reported price is value ÷ shares from the 13F as of period end — not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2023 Q2. Click column headers to sort · click New / Hold / Add / Reduce to promote that move type to the top. Exit opens the last-held block below.

Filings history

20 periods · normalized AUM · open a period for holdings

Period Holdings AUM QoQ Form Filed Filing ID
2026 Q2 8 $2.6B −17.2% 13F-HR 8/14/2026 000101359426000913
2026 Q1 9 $3.1B −4.6% 13F-HR 5/15/2026 000101359426000611
2025 Q4 9 $3.3B +9.9% 13F-HR 2/17/2026 000101359426000257
2025 Q3 10 $3B +47.6% 13F-HR 11/14/2025 000101359425001436
2025 Q2 15 $2B +15.1% 13F-HR 8/14/2025 000101359425001044
2025 Q1 14 $1.7B +5.8% 13F-HR 5/15/2025 000101359425000679
2024 Q4 13 $1.7B +15.9% 13F-HR 2/14/2025 000101359425000309
2024 Q3 15 $1.4B +5.3% 13F-HR 11/14/2024 000101359424000980
2024 Q2 16 $1.4B −6.6% 13F-HR 8/14/2024 000101359424000667
2024 Q1 18 $1.4B +30.7% 13F-HR 5/15/2024 000101359424000487
2023 Q4 17 $1.1B −0.9% 13F-HR 2/14/2024 000101359424000197
2023 Q3 18 $1.1B +9.2% 13F-HR 11/14/2023 000101359423000930
2023 Q2 21 $1B −14.9% 13F-HR 8/14/2023 000101359423000696
2023 Q1 20 $1.2B +8.3% 13F-HR 5/15/2023 000101359423000494
2022 Q4 22 $1.1B −18.7% 13F-HR 2/14/2023 000101359423000262
2022 Q3 28 $1.4B −32.6% 13F-HR 11/14/2022 000156761922020074
2022 Q2 32 $2B −37.6% 13F-HR 8/15/2022 000156761922016238
2022 Q1 33 $3.2B +0.2% 13F-HR 5/16/2022 000156761922011018
2021 Q4 36 $3.2B −7.6% 13F-HR 2/14/2022 000156761922004409
2021 Q3 38 $3.5B 13F-HR 11/15/2021 000156761921020479

About

Paulson & Co. Inc.

20 processed 13Fs on this site · 2021 Q3–2026 Q2

Entity
Paulson & Co. Inc.
Notable person
John Paulson
Location
Jersey City, NJ
All SEC filings
View on sec.gov